Nexopamil (LU 49938), A Combined Ca 2+ Channel Blocker and 5HT 2 Receptor Antagonist
- 1 September 1994
- journal article
- Published by Wiley in Cardiovascular Drug Reviews
- Vol. 12 (3) , 195-207
- https://doi.org/10.1111/j.1527-3466.1994.tb00205.x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Protection of Reperfused Ischemic Pig Myocardium by Nexopamil, a New Combined Ca2+ and Serotonin AntagonistJournal of Cardiovascular Pharmacology, 1994
- Inhibition by the Combined Ca2+ and 5-HT2 Receptor Antagonist Nexopamil (LU 49938) of Intracoronary Thrombus Formation in a Canine Model of Arterial Stenosis and Intimal DamageJournal of Cardiovascular Pharmacology, 1993
- Effect of Intracoronary Serotonin on Coronary Vessels in Patients with Stable Angina and Patients with Variant AnginaNew England Journal of Medicine, 1991
- Divergent Effects of Serotonin on Coronary-Artery Dimensions and Blood Flow in Patients with Coronary Atherosclerosis and Control PatientsNew England Journal of Medicine, 1991
- Cardiovascular and Renal Actions of AHR-16303B, an Antagonist of 5-HT2 Receptors and CalciumChannels, in Hypertensive and Nomotensive RatsJournal of Cardiovascular Pharmacology, 1991
- AHR-16303B, a Novel Antagonist of 5-HT2 Receptors and Voltage-Sensitive Calcium ChannelsJournal of Cardiovascular Pharmacology, 1991
- Clinical Pharmacokinetics of VerapamilClinical Pharmacokinetics, 1984
- Coronary reserve in spontaneously hypertensive rats: the effect of blood pressure, hypertrophy and longterm vasodilator therapyPublished by Springer Nature ,1983
- Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dogCardiovascular Research, 1978
- Platelet aggregation in partially obstructed vessels and its elimination with aspirin.Circulation, 1976